Mangrove Partners Savara Inc Transaction History

Mangrove Partners

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$2.37 - $11.7 $1.93 Million - $9.52 Million	-813,615 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$6.27 - $10.92 $3.83 Million - $6.68 Million	611,467 Added 302.48%	813,615 $6.16 Million
Q3 2018 Nov 14, 2018	BUY	$10.49 - $12.87 $2.12 Million - $2.6 Million	202,148 New	202,148 $2.26 Million

129

158M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $357M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Mangrove Partners, based on Form 13F filings with the SEC.

Stay updated on Mangrove Partners with notifications on news.